Media Africa 247

Wednesday, May 27, 2026

Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds

WINDSOR, Conn. - Wednesday, 27. May 2026

(BUSINESS WIRE)--SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including:

Royal London Global Equity Diversified Fund

Royal London Global Equity Enhanced Fund

Royal London Global Equity Select Fund

Royal London Short Duration Global High Yield Bond Fund

RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range.

Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investment in Transferable Securities (UCITS) funds.

SS&C will provide its full suite of fund administration services to the funds, including fund accounting, unit pricing, transfer agency, valuation and tax/financial reporting.

“We are thrilled to extend our partnership with SS&C to encompass our new range of Australian funds,” said Ed Venner, Chief Client Officer at Royal London Asset Management. “We’ve been partnering with SS&C for the last three years in the U.K. with positive results. The firm’s global scale and their growing presence in the Australian market made SS&C a natural choice to service our new Australian funds. SS&C’s expertise has streamlined the unit trust launch process for our team, allowing us to focus on building direct relationships with Australian investors and advisers.”

“We are pleased to further our long-term relationship with Royal London Asset Management as they continue developing their distribution model in the growing Australian market,” said Nick Wright, Global Head of SS&C Global Investor & Distribution Solutions. “SS&C has invested significant time and resources in expanding our local team and offerings to best serve fund managers in the region. We are honored RLAM has entrusted us with supporting their new range of Australian funds and look forward to continuing to work with their team.”

The announcement follows a wave of recent Australian growth for SS&C, including a number of client wins and renewals across superannuation and wealth. To support growth in the APAC business, the firm recently hired Chrys Wickremeratne to serve as Regional Head of Fund Accounting. Wickremeratne brings 25 years of experience across Australian financial services, and most recently served as Head of Fund Services for Australia and New Zealand at HSBC.

About Royal London Asset Management

Royal London Asset Management is an integral part of customer-owned mutual, Royal London, and free from short-term shareholder demands.

Managing £199 billion* on behalf of a broad range of clients, Royal London Asset Management is committed to active investment excellence and responsible investing. It works in close partnership with clients to deliver a spectrum of investment solutions to help investors navigate complex market conditions and achieve their financial goals.

*As at 31 December 2025

About SS&C Technologies

SS&C is a global provider of services and software for the financial services and healthcare industries. Founded in 1986, SS&C is headquartered in Windsor, Connecticut, and has offices around the world. More than 23,000 financial services and healthcare organizations, from the world's largest companies to small and mid-market firms, rely on SS&C for expertise, scale and technology.

SOURCE: SS&C

Additional information about SS&C (Nasdaq: SSNC) is available at www.ssctech.com.

Follow SS&C on X, LinkedIn and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260526658174/en/

Permalink

https://www.aetoswire.com/en/news/54542183

Contacts

Brian Schell | Chief Financial Officer, SS&C Technologies

Tel: +1-816-642-0915 | E-mail: InvestorRelations@sscinc.com

Justine Stone | Investor Relations, SS&C Technologies

Tel: +1-212-367-4705 | E-mail: InvestorRelations@sscinc.com

Media Contacts

Breanna Taylor

Prosek Partners

Email: pro-SSC@prosek.com

NIQ Launches Survey Groups to Connect Consumer Sentiment with Real Purchase Behavior

CHICAGO -

New integrated capability connects consumer sentiment with real-world purchase data, enabling more confident, action‑driven decisions

(BUSINESS WIRE)--NIQ (NYSE: NIQ), a global leader in consumer intelligence, today announced the launch of Survey Groups in NIQ Discover, a new capability that enables brands and retailers to understand not just what is changing in the market, but why.

Available immediately within NIQ Discover, Survey Groups build on NIQ Panel Surveys by linking attitudinal insights to real-world purchase behavior from NIQ’s consumer panels—helping clients uncover the motivations behind performance shifts, identify opportunity gaps, and act with greater confidence in an increasingly complex consumer landscape.

What’s New: Survey Groups in Discover

Survey Groups make NIQ Panel Survey insights easier to access, analyze, and activate within existing workflows. By grouping survey responses with purchase behavior, clients can:

Analyze key consumer segments with greater precision

Understand the drivers behind brand and category performance

Identify barriers to purchase and causes of brand or category lapsing

Surface emerging growth opportunities rooted in real behavior

Create self-serve analyses directly within Discover

Why It Matters: Moving Beyond Claimed Behavior

As consumer decision‑making becomes more fragmented and unpredictable, traditional surveys often based solely on claimed behavior can fall short of explaining real‑world outcomes. Survey Groups address this gap by tying what consumers say directly to what they do. This integration allows businesses to move beyond surface‑level insights and gain a deeper, more reliable understanding of motivations, helping teams prioritize actions that inform growth strategies.

“NIQ has delivered Panel Survey capabilities for many years, helping clients understand the motivations behind consumer behavior through verified purchase data,” said Troy Treangen, Chief Product Officer at NIQ. “What’s new with Survey Groups is that these insights are now integrated directly into Discover, making them easier to access, analyze, and activate within existing workflows. By bringing survey insights and consumer behavior together in one platform, clients can move faster from insight to action with a more connected view of performance.”

How It Works: Sentiment Meets Verified Purchase Data

Survey Groups are powered by NIQ Panel Surveys, which are directly connected to NIQ’s robust consumer panels in the FMCG industry. This linkage provides a more representative view of consumer behavior, grounding insights in transactional purchase data rather than intention alone.

Within NIQ Discover, the same surveyable population can be analyzed while maintaining consistent sample coverage as Survey Groups are activated for deeper analysis. Teams can independently create and analyze Survey Groups at the question-and answer-level, enabling self-serve segmentation across markets. By bringing these insights into Discover, NIQ enables faster analysis, easier collaboration, and more confident decision‑making across teams.

What’s Next: Continued Investment in Panel Surveys

Survey Groups represent the first step in a broader roadmap for NIQ Panel Surveys. NIQ will continue to invest in making these insights more accessible, actionable, and deeply integrated within Discover, with additional enhancements planned throughout 2026 and beyond.

These advancements support NIQ’s broader strategy to unify measurement, panel, and survey insights within a single platform enabling faster, clearer, and more confident decision‑making for clients worldwide.

As consumer behavior grows more complex, the ability to connect motivations to outcomes is becoming a critical advantage. By integrating survey sentiment with real-world purchase behavior, Survey Groups help brands and retailers turn insight into action—closing gaps between understanding and execution, and enabling more informed, confident decision-making.

In a market where knowing why matters as much as knowing what, NIQ is redefining how consumer intelligence powers performance. For more information visit NIQ Discover.

Frequently Asked Questions:

Q: What are NIQ Survey Groups?

A: Survey Groups are a new capability within NIQ Discover that connect consumer survey responses directly to real-world purchase behavior from NIQ’s consumer panels, enabling deeper insight into the motivations behind market performance.

Q: How are NIQ Survey Groups different from traditional surveys?

A: Traditional surveys rely on claimed or self‑reported behavior, which can differ from actual actions. Survey Groups link what consumers say with what they actually buy, providing a more accurate view of consumer decision‑making.

Q: Who can benefit from Survey Groups?

A: Survey Groups are designed for brands, retailers, and manufacturers looking to understand the drivers behind brand and category performance, identify growth opportunities, reduce churn or lapsing, and make more confident, data‑driven decisions.

Q: Where are Survey Groups available?

A: Survey Groups are available directly within NIQ Discover, allowing clients to access, analyze, and apply these insights within their existing workflows.

Q: What types of insights do Survey Groups deliver?

A: Survey Groups help uncover key consumer segments, drivers of brand and category growth or decline, barriers to purchase, reasons for lapsing, and emerging opportunities—grounded in real purchasing behavior.

Q: How do Survey Groups support faster decision‑making?

A: By integrating survey, panel, and measurement data in a single platform, Survey Groups make insights easier to access and apply, reducing time to insight and enabling teams to move from analysis to action more quickly.

Q: Is this a standalone launch or part of a broader roadmap?

A: Survey Groups represent the first step in a broader set of enhancements to NIQ Panel Surveys. NIQ will continue to invest in expanding and improving these capabilities throughout 2026 and beyond.

Q: How does this fit into NIQ’s overall strategy?

A: Survey Groups support NIQ’s mission to deliver the Full View™ of consumer behavior by connecting measurement, panel, and survey insights in a single, integrated platform—helping clients navigate increasingly complex consumer ecosystems with confidence.

About NIQ

NielsenIQ (NYSE: NIQ) is a leading consumer intelligence company, delivering the most complete and trusted understanding of consumer buying behavior and revealing the pathways to growth. By combining an unmatched global data footprint and granular consumer and retail measurement with decades of AI modeling expertise, NIQ builds decision systems that help companies turn complex data into confident action.

With operations in more than 90 countries, NIQ covers approximately 82% of the world’s population and more than $7.4 trillion in global consumer spend. Through cloud-based platforms, advanced analytics and AI-driven insights, NIQ delivers The Full View™—helping brands and retailers understand what consumers buy, why they buy it, and what to do next.

For more information, please visit www.niq.com.

NIQ-GENERAL

View source version on businesswire.com: https://www.businesswire.com/news/home/20260527348264/en/

Permalink

https://www.aetoswire.com/en/news/54541994

Contacts

Media Contact:

NIQ: media.relations@niq.com

Monday, May 25, 2026

JEOL: Sales Launch of the Laser SEM System “LazEdge”

(BUSINESS WIRE) -- JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026.

Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope.

This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a result, it meets a wide range of analytical needs, including metal specimen analysis, battery analysis requiring air-isolation, and semiconductor failure analysis requiring high-speed cross-sectioning.

[Main Features]

1. High-quality cross-sectioning inside the specimen chamber

By integrating a laser processing system into the SEM, LazEdge achieves high-quality cross-sectioning of large-areas with reduced LIPSS structures at a high speed in the specimen chamber, through the use of a proprietary optical system that enables phase modulation of the laser beam spatially.

2. Stable and clean processing enabled by “LazEdge Shield”

The proprietary shielding technology “LazEdge Shield”, minimizes debris generated during processing from scattering, and achieves clean processing without the contamination of detectors, columns, and specimen chamber walls. Moreover, the laser system can simultaneously focus on the specimen processing position and the laser irradiation position on the shield. This technology allows for processing and cleaning of the shield (contamination prevention) at the same time. These technologies provide high-quality cross-sectioning while always maintaining stable power.

3. Seamless, high-throughput processing and observation

By installing a shield inside the SEM specimen chamber and performing the processing within the chamber, it is possible to carry out both processing and observation seamlessly and with high throughput. For example, in EBSD measurements, laser processing alone can produce cross-section with sufficient quality for EBSD measurement. By automatically repeating the processing and measurement, 3D EBSD acquisition is also possible.

[Sales target] 10 units/year

The LYCRA Company and Dukane Advance Ultrasonic Bonding for Nonwovens at INDEX™ 26

LYCRA FUSION™ Fiber for Personal Care Applications Debuts

(BUSINESS WIRE)--The LYCRA Company, a global leader in innovative and sustainable fiber solutions for the personal care industry, and Dukane, a manufacturer of ultrasonic bonding technologies for the hygiene and nonwovens market, are showcasing their latest co-developed advances in ultrasonic bonding at INDEX™ 26, taking place in Geneva, Switzerland, from May 19–22.

Since 2014, both companies have collaborated to advance ultrasonic bonding solutions that help diaper manufacturers improve product softness, fit, and performance while reducing energy consumption, material waste, and maintenance costs. Ultrasonic bonding creates bonded channels between two layers of nonwoven materials, mechanically securing elastic fibers without using adhesives. Dukane’s patented rotary and rigid ultrasonic bonding systems enable high-speed, adhesive-free assembly by delivering precisely controlled ultrasonic energy into nonwoven substrates.

LYCRA FUSION™ fiber, originally developed to prevent snags in hosiery from turning into runs, can now fuse to nonwoven layers during ultrasonic bonding. Its sheath/core construction fuses with surrounding materials, strengthens ultrasonic bonds, and delivers superior yarn creep (snapback). When this fiber is paired with Dukane’s advanced ultrasonic bonding modules, manufacturers can achieve precise elastic placement, improved bond integrity, and consistent product performance while eliminating the variability associated with hot-melt adhesives.

“As ultrasonic bonding gains traction in the hygiene industry, our longstanding collaboration with Dukane focuses on expanding technical capabilities while preparing for commercial scale-up,” said Doug Kelliher, executive vice president, product, The LYCRA Company. “We’re excited to introduce LYCRA FUSION™ fiber for personal care, which provides excellent performance with fewer breaking points and improved bond integrity during the ultrasonic bonding process.”

Building on this shared commitment to innovation, The LYCRA Company and Dukane are aligning fiber development with ultrasonic process engineering to support broader adoption of adhesive‑free elastic attachment in nonwovens.

“From ultrasonic lamination to precision sealing and cutting, our technologies are engineered for consistent quality, global scalability, and sustainable production,” said Justin Lafferty, global product development manager - nonwovens, Dukane. “By advancing ultrasonic bonding with LYCRA FUSION™ fiber, we’re helping customers improve product performance while enabling more efficient production.”

Explore more hygiene and nonwovens solutions at The LYCRA Company stand (2151) and the Dukane stand (1568) at INDEX™ 26.

About The LYCRA Company

The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries and owns the leading consumer brands: LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX® and TACTEL®. Headquartered in Wilmington, Delaware, U.S., The LYCRA Company is recognized worldwide for its sustainable products, technical expertise, and marketing support. The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. Learn more at thelycracompany.com.

About Dukane

Headquartered in St. Charles, DUKANE is a global leader in ultrasonic bonding technologies for the hygiene and personal care industries. Unlike single-approach bonding systems, Dukane offers a range of ultrasonic bonding modules designed to replace adhesive-based processes in hygiene and personal care manufacturing. Manufacturers can select the right bonding technology based on product design, production speed, and long-term operational goals. Dukane’s flexible platform supports intermittent and continuous bonding, as well as blade and rotary technologies, without locking manufacturers into a single technology path. Learn more at dukane.com/nonwoven.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260515514441/en/

Permalink

https://www.aetoswire.com/en/news/54536259

Contacts

Karie J. Ford

Karie.j.ford@lycra.com

Shivani Singh

ssingh@dukane.com

MOBX to Acquire U.S. Defense Rare Earth, Critical Minerals Company

(BUSINESS WIRE)--Mobix Labs (Nasdaq: MOBX) today announced a non-binding Letter of Intent to acquire Special Project Delivery LLC ("SPD"), a U.S. company building sovereign supply chains for rare earth elements, critical minerals, and energy storage.

The proposed acquisition would extend Mobix Labs' national security work — already supplying U.S. and allied fighter jets, missiles, submarines, and satellites — directly into one of the world's most strategically important industrial sectors. MOBX is moving directly into the supply chain powering modern defense, aerospace, and AI infrastructure.

Forward-Looking Statements

This press release contains forward-looking statements regarding the proposed acquisition of Special Project Delivery LLC ("SPD"), which are subject to risks and uncertainties described in Mobix Labs' SEC filings and similar provisions under applicable non-U.S. securities laws. The Letter of Intent is non-binding, and there can be no assurance that a definitive agreement will be executed or the proposed transaction completed.

Follow on StockTwits: MobixLabs

View source version on businesswire.com: https://www.businesswire.com/news/home/20260514428219/en/

Permalink

https://www.aetoswire.com/en/news/1405202655082

Contacts

MOBX Investor Relations Contacts

Chris Eddy or David Collins

Catalyst IR

mobx@catalyst-ir.com or 212-924-9800

Sunday, May 24, 2026

The Estée Lauder Companies & Puig End Discussions Regarding a Potential Business Combination

The Estée Lauder Companies Reiterates Confidence in Its Beauty Reimagined Strategic Vision

(BUSINESS WIRE) -- On March 23, 2026, The Estée Lauder Companies Inc. (NYSE: EL) and Puig confirmed they were in discussions regarding a potential business combination, but unless and until an agreement was signed between the companies, there could be no assurances regarding the deal or its terms.

The Estée Lauder Companies and Puig today announced that the parties have terminated discussions regarding a potential business combination. The Estée Lauder Companies remains fully focused on continuing to execute its Beauty Reimagined strategy, which is well underway and delivering positive results.

“We are grateful for the conversations we have had with Puig,” said Stéphane de La Faverie, President and Chief Executive Officer of The Estée Lauder Companies. “Today, we are reiterating our confidence in the power of our incredible brands, our talented teams, and our strength as a standalone company. We are more optimistic than ever about our ability to unlock significant long-term value through Beauty Reimagined, and we remain focused on accelerating that progress.

We have one of the most powerful portfolios of prestige beauty brands in the world, supported by exceptional equity across categories, geographies, and consumer segments, and we believe we are uniquely positioned to drive sustainable long-term growth globally.

The momentum we are seeing across our business reinforces the strength of the path ahead. Through Beauty Reimagined and the implementation of our ‘One ELC’ operating model, we are building a faster, more agile, consumer-focused organization — one that is accelerating innovation, strengthening execution, scaling winning ideas globally, and investing behind the highest-growth opportunities across our portfolio.

At the same time, we will continue to evaluate and evolve our portfolio to ensure we have the right assets to drive the most compelling growth opportunities, including both potential acquisitions and divestitures.

We remain relentlessly focused on driving sustainable sales growth, expanding profitability, and delivering a solid double-digit adjusted operating margin over time, all while creating long-term value for stockholders.”

Forward-Looking Statements

The forward-looking statements in this press release, including those in the quoted remarks and those relating to the benefits and other expectations, involve risks and uncertainties. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Factors that could cause actual results to differ from those forward-looking statements include current economic and other conditions, including volatility, in the global marketplace, actions by retailers, suppliers and consumers, competition, and those risk factors described in The Estée Lauder Companies’ annual report on Form 10-K for the year ended June 30, 2025. The Estée Lauder Companies undertakes no obligation to update any forward-looking statements, except as required by law.

About The Estée Lauder Companies Inc.

The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products, and is a steward of luxury and prestige brands globally. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, the DECIEM family of brands, including The Ordinary and NIOD, and BALMAIN Beauty.

ELC-C

View source version on businesswire.com: https://www.businesswire.com/news/home/20260521769350/en/

Permalink

https://aetoswire.com/en/news/2205202655236

Contacts

Investor Relations:

Rainey Mancini

rmancini@estee.com

Media Relations:

Brendan Riley

briley@estee.com

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch

ZUG, Switzerland - Saturday, 23. May 2026 AETOSWire Print

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older

Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage

Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter

The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone

(BUSINESS WIRE) -- Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care.

This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care.

With the approval of Differin Epiduo OTC, Galderma is bringing its proven acne science to a broader population of acne sufferers through wider access to a dermatologist-recommended, prescription-strength treatment, while further strengthening its global leadership in acne care.

Delivering continued innovation in acne prevention and care

Differin Epiduo is a topical acne treatment that combines adapalene, a third-generation retinoid originally discovered and developed by Galderma to address the stability and tolerability challenges of earlier retinoids, with benzoyl peroxide (0.1/2.5%). This adapalene molecule reflects Galderma’s long-standing leadership in retinoid science, delivering an innovation-led approach that goes beyond traditional OTC acne actives. Together, these two dermatologist-trusted ingredients address key biological drivers of acne – clearing clogged pores, killing acne-causing bacteria, and reducing acne inflammation – to help clear acne, prevent future breakouts and improve skin tone, texture, and overall appearance.1,2

The formulation is further powered by its Simulgel™ Gel Base, which stabilizes and evenly distributes both active ingredients while maintaining benzoyl peroxide’s efficacy and improving overall tolerability. This enables a simple, one-pump, once-daily regimen – a level of ease that is critical to building consistent routines and achieving clearer skin over time.

“This approval marks an important milestone in acne care and reflects Galderma’s longstanding leadership in acne and retinoid science. Differin Epiduo pairs two complementary, evidence‑based actives: adapalene, a highly stable and well‑tolerated retinoid developed by Galderma, and benzoyl peroxide, a proven antimicrobial agent. This retinoid-benzoyl peroxide combination aligns with dermatology guidelines, which strongly recommend using both together as a first‑line, multimodal approach to acne treatment. Bringing this scientifically grounded combination to the OTC setting allows us to extend that legacy to patients across the U.S. while preserving the clinical rigor that underpins its effectiveness.”

BILL ANDRIOPOULOS, PH.D.

HEAD OF GLOBAL MEDICAL AFFAIRS

GALDERMA

Clinical data supporting the approval demonstrated:

Proven efficacy across multiple randomized, controlled Phase 3 studies, with adapalene/benzoyl peroxide gel consistently outperforming adapalene alone, benzoyl peroxide alone, and vehicle gel across inflammatory, non-inflammatory, and total acne lesions, as well as Investigator Global Assessment (IGA) success rates (“clear” or “almost clear”).3-5

Clinically meaningful improvement in lesion counts seen as early as Week 1, with antimicrobial activity beginning on Day 1 and up to 70.3% reduction in inflammatory acne lesions at Week 12.3

Sustained efficacy with long‑term use, maintaining ~65% total lesion reduction in a single arm study through 12 months, which supports once‑daily, ongoing acne control.6

Proven efficacy across diverse patient populations, with consistent results and favorable tolerability across skin tones.

“This milestone reflects a meaningful advancement for patients, as it expands access to a clinically proven, dual-active acne solution without the need for a prescription. In my practice, the combination of easy access and a simple, once-daily application can help patients use treatment more consistently in their treatment journey for the best possible outcomes.”

HEATHER WOOLERY-LLOYD, MD

BOARD-CERTIFIED DERMATOLOGIST

UNITED STATES

First approved as a prescription treatment, Epiduo® (Adapalene 0.1% and Benzoyl Peroxide 2.5%) Gel has been trusted by dermatologists for more than 15 years, with millions of prescriptions written worldwide. Its global clinical legacy includes more than ten Galderma studies involving over 3,200 patients, along with extensive third-party studies, across a wide range of ages, skin tones and acne severity. With this Prescription-to-OTC switch, Galderma continues to play a defining role in shaping modern acne care, leveraging its own proprietary science to advance dermatology, and expanding access to effective treatments.

Differin Epiduo will be available over-the-counter at most major retailers, including Walmart, Ulta, Target and Amazon, beginning in the summer of 2026. With a commitment to providing effective solutions across consumers’ acne journey, the Differin portfolio also includes cleansers, treatments, and moisturizers to support and provide wholistic solutions. For more information on Differin Epiduo and other Differin products, please visit www.differin.com and join the Differin community on Instagram, Facebook and YouTube to stay up to date on the latest innovations.

* Outside of the U.S. Epiduo® remains a prescription only product.

About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ—the skin—meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References:

Reynolds RV et al. J Am Acad Dermatol. 2024. doi:10.1016/j.jaad.2023.12.017.

Del Rosso JQ, J Clin Aesthet Dermatol. 2015.

Gollnick HP et al. Br J Dermatol. 2009;161(5):1180-1189.

Stein Gold L et al. Cutis. 2009;84(2):110-116.

Thiboutot DM et al. J Am Acad Dermatol. 2007;57(5):791-799.

Pariser et al JDD 2007 Sep;6(9):899-905.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260522074280/en/

Permalink

https://www.aetoswire.com/en/news/2305202655273

Contacts

For further information:

Christian Marcoux, M.Sc.

Chief Communications Officer

christian.marcoux@galderma.com

+41 76 315 26 50

Céline Buguet

Franchises and R&D Communications Director

celine.buguet@galderma.com

+41 76 249 90 87

Viviana Wiewall

Head of U.S. Communications

viviana.wiewall@galderma.com

+1 786 451 7740

Emil Ivanov

Head of Strategy, Investor Relations, and ESG

emil.ivanov@galderma.com

+41 21 642 78 12

Jessica Cohen

Investor Relations and Strategy Director

jessica.cohen@galderma.com

+41 21 642 76 43